Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/15169
|
| Title: | Low-dose computed tomography screening in relatives with a family history of lung cancer |
| Authors: | Wang, CL;Hsu, KH;Chang, YH;Ho, CC;Chiang, CJ;Chen, KC;Cheung, YC;Huang, PC;Chen, YR;Chen, CY;Hsu, CP;Hsia, JY;Chen, HY;Yang, SY;Li, YJ;Yang, TY;Tseng, JS;Chuang, CY;Hsiung, CA;Chen, YM;Huang, MS;Yu, CJ;Chen, KY;Su, WC;Chen, JJW;Yu, SL;Chen, CJ;Yang, PC;Tsai, YH;Chang, GC |
| Contributors: | Institute of Molecular and Genomic Medicine;Institute of Population Health Sciences |
| Abstract: | BACKGROUND: The role of family history of lung cancer (LCFH) in screening using low-dose computed tomography (LDCT) has not been prospectively investigated and with long-term follow-up. METHODS: A multicenter prospective study with up to three rounds of annual LDCT screening was conducted to determine the detection rate of LC in asymptomatic first or second-degree relatives of LCFH. RESULTS: From 2007 to 2011, there were 1,102 participants enrolled, including 805 and 297 from simplex (SF) and multiplex families (MF), respectively (54.2% female, and 70.0% never-smokers). Last follow-up date was May 05, 2021. The overall LC detection rate was 4.5% (50/1102). The detection rate in MF was 9.4% (19/202) and 4.4% (4/91) in never-smokers and who smoked, respectively. The corresponding rates for SF were 3.7% (21/569) and 2.7% (6/223), respectively. Of them, 68.0% and 22.0% of cases with stage I and IV diseases, respectively. LC diagnoses within a 3-year interval from initial screening were younger, higher detection rate, and more stage I disease; thereafter, more stage III/IV disease and 66.7% (16/24) with negative or semi-positive nodules in initial CT scans. Within the 6-year interval, only maternal (modified rate ratio [RR]=4.46, 95% confidence interval [CI]=2.32-8.56) or maternal relative history of LC (modified RR=5.41, 95% CI=2.84-10.30) increased the risk of LC. CONCLUSION: LCFH is a risk factor for LC, more in MF history, never-smokers, younger adults, and those with maternal relatives with LC. Randomized controlled trials are needed to confirm mortality benefit of LDCT screening in those with LCFH. |
| Date: | 2023-11 |
| Relation: | Journal of Thoracic Oncology. 2023 Nov;18(11):1492-1503. |
| Link to: | http://dx.doi.org/10.1016/j.jtho.2023.06.018 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1556-0864&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:001107589200001 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85169454773 |
| Appears in Collections: | [熊昭] 期刊論文
[張雅媗] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| PUB37414358.pdf | | 712Kb | Adobe PDF | 119 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
